The Impact of Aqueous Solubility and Dose on the Pharmacokinetic Profiles of Resveratrol (original) (raw)
References
J. A. Baur, and D.A. Sinclair. Therapeutic potential of resveratrol: the in vivo evidence. Nat. Rev. Drug. Discov.5:493–506 (2006). ArticlePubMedCAS Google Scholar
J. A. Baur, K. J. Pearson, N. L. Price, H. A. Jamieson, C. Lerin, A. Kalra, V. V. Prabhu, J. S. Allard, G. Lopez-Lluch, K. Lewis, P. J. Pistell, S. Poosala, K. G. Becker, O. Boss, D. Gwinn, M. Wang, S. Ramaswamy, K. W. Fishbein, R. G. Spencer, E. G. Lakatta, D. Le Couteur, R. J. Shaw, P. Navas, P. Puigserver, D. K. Ingram, R. de Cabo, and D. A. Sinclair. Resveratrol improves health and survival of mice on a high-calorie diet. Nature. 444:337–342 (2006) doi:10.1038/nature05354. ArticlePubMedCAS Google Scholar
M. Jang, L. Cai, G. O. Udeani, K. V. Slowing, C. F. Thomas, C. W. Beecher, H. H. Fong, N. R. Farnsworth, A. D. Kinghorn, R. G. Mehta, R. C. Moon, and J. M. Pezzuto. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 275:218–220 (1997) doi:10.1126/science.275.5297.218. ArticlePubMedCAS Google Scholar
D. Delmas, A. Lancon, D. Colin, B. Jannin, and N. Latruffe. Resveratrol as a chemopreventive agent: a promising molecule for fighting cancer. Curr. Drug Targets. 7:423–442 (2006) doi:10.2174/138945006776359331. ArticlePubMedCAS Google Scholar
T. Walle, F. Hsieh, M. H. DeLegge, J. E. Oatis Jr., and U. K. Walle. High absorption but very low bioavailability of oral resveratrol in humans. Drug Metab. Dispos.32:1377–1382 (2004) doi:10.1124/dmd.104.000885. ArticlePubMedCAS Google Scholar
D. J. Boocock, G. E. Faust, K. R. Patel, A. M. Schinas, V. A. Brown, M. P. Ducharme, T. D. Booth, J. A. Crowell, M. Perloff, A. J. Gescher, W. P. Steward, and D. E. Brenner. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol. Biomarkers Prev.16:1246–1252 (2007) doi:10.1158/1055-9965.EPI-07-0022. ArticlePubMedCAS Google Scholar
S. Hurst, C.M. Loi, J. Brodfuehrer, and A. El-Kattan. Impact of physiological, physicochemical and biopharmaceutical factors in absorption and metabolism mechanisms on the drug oral bioavailability of rats and humans. Expert Opin. Drug Metab. Toxicol.3:469–489 (2007) doi:10.1517/17425255.3.4.469. ArticlePubMedCAS Google Scholar
M. I. Kaldas, U. K. Walle, and T. Walle. Resveratrol transport and metabolism by human intestinal Caco-2 cells. J. Pharm. Pharmacol.55:307–312 (2003) doi:10.1211/002235702612. ArticlePubMedCAS Google Scholar
A. Maier-Salamon, B. Hagenauer, M. Wirth, F. Gabor, T. Szekeres, and W. Jager. Increased transport of resveratrol across monolayers of the human intestinal Caco-2 cells is mediated by inhibition and saturation of metabolites. Pharm. Res.23:2107–2115 (2006) doi:10.1007/s11095-006-9060-z. ArticlePubMedCAS Google Scholar
V. Bertacche, N. Lorenzi, D. Nava, E. Pini, and C. Sinico. Host–guest interaction study of resveratrol with natural and modified cyclodextrins. J. Incl. Phenom. Macrocycl. Chem.55:279–287 (2006) doi:10.1007/s10847-006-9047-8. ArticleCAS Google Scholar
J. F. Marier, P. Vachon, A. Gritsas, J. Zhang, J. P. Moreau, and M. P. Ducharme. Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther.302:369–373 (2002) doi:10.1124/jpet.102.033340. ArticlePubMedCAS Google Scholar
C. Yu, Y. G. Shin, A. Chow, Y. Li, J. W. Kosmeder, Y. S. Lee, W. H. Hirschelman, J. M. Pezzuto, R. G. Mehta, and R. B. van Breemen. Human, rat, and mouse metabolism of resveratrol. Pharm. Res.19:1907–1914 (2002) doi:10.1023/A:1021414129280. ArticlePubMedCAS Google Scholar
A. J. Gescher, and W. P. Steward. Relationship between mechanisms, bioavailibility, and preclinical chemopreventive efficacy of resveratrol: a conundrum. Cancer Epidemiol. Biomarkers Prev.12:953–957 (2003). PubMedCAS Google Scholar
M. E. Davis, and M. E. Brewster. Cyclodextrin-based pharmaceutics: past, present and future. Nat. Rev. Drug Discov.3:1023–1035 (2004) doi:10.1038/nrd1576. ArticlePubMedCAS Google Scholar
A. Katsagonis, J. Atta-Politou, and M. A. Koupparis. HPLC method with UV detection for the determination of _trans_-resveratrol in plasma. J. Liq. Chromatogr. Relat. Technol.28:1393–1405 (2005) doi:10.1081/JLC-200054884. ArticleCAS Google Scholar
H. S. Lin, C. S. Chean, Y. Y. Ng, S. Y. Chan, and P. C. Ho. 2-hydroxypropyl-beta-cyclodextrin increases aqueous solubility and photostability of all-trans-retinoic acid. J. Clin. Pharm. Ther.25:265–269 (2000) doi:10.1046/j.1365-2710.2000.00285.x. ArticlePubMedCAS Google Scholar
T. Higuchi, and K. A. Connors. Phase-solubility techniques. Advan. Anal. Chem. Instr.4:117–212 (1965). CAS Google Scholar
H. S. Lin, W. W. Leong, J. A. Yang, P. Lee, S. Y. Chan, and P. C. Ho. Biopharmaceutics of 13-cis-retinoic acid (isotretinoin) formulated with modified beta-cyclodextrins. Int. J. Pharm.341:238–245 (2007) doi:10.1016/j.ijpharm.2007.03.050. ArticlePubMedCAS Google Scholar
H. S. Lin, A. B. Barua, J. A. Olson, K. S. Low, S. Y. Chan, M. L. Shoon, and P. C. Ho. Pharmacokinetic study of all-trans-retinoyl-beta-d-glucuronide in Sprague–Dawley rats after single and multiple intravenous administration(s). J. Pharm. Sci.90:2023–2031 (2001) doi:10.1002/jps.1153. ArticlePubMedCAS Google Scholar
K. Uekama, and M. Otagiri. Cyclodextrins in drug carrier systems. Crit. Rev. Ther. Drug Carr. Syst.3:1–40 (1987). CAS Google Scholar
C. F. Hung, Y. K. Lin, Z. R. Huang, and J. Y. Fang. Delivery of resveratrol, a red wine polyphenol, from solutions and hydrogels via the skin. Biol. Pharm. Bull.31:955–962 (2008) doi:10.1248/bpb.31.955. ArticlePubMedCAS Google Scholar
G. Piel, B. Evrard, T. Van Hees, and L. Delattre. Comparison of the IV pharmacokinetics in sheep of miconazole–cyclodextrin solutions and a micellar solution. Int. J. Pharm.180:41–45 (1999) doi:10.1016/S0378-5173(98)00403-7. ArticlePubMedCAS Google Scholar
Z. Lu, Y. Zhang, H. Liu, J. Yuan, Z. Zheng, and G. Zou. Transport of a cancer chemopreventive polyphenol, resveratrol: interaction with serum albumin and hemoglobin. J. Fluoresc.17:580–587 (2007) doi:10.1007/s10895-007-0220-2. ArticlePubMedCAS Google Scholar
O. H. Chan, and B. H. Stewart. Physicochemical and drug delivery considerations for oral drug bioavailability. Drug Discov. Today. 1:461–473 (1996) doi:10.1016/1359-6446(96)10039-8. Article Google Scholar
C. De Santi, A. Pietrabissa, R. Spisni, F. Mosca, and G. M. Pacifici. Sulphation of resveratrol, a natural product present in grapes and wine, in the human liver and duodenum. Xenobiotica. 30:609–617 (2000) doi:10.1080/004982500406435. ArticlePubMed Google Scholar
W. Andlauer, J. Kolb, K. Siebert, and P. Furst. Assessment of resveratrol bioavailability in the perfused small intestine of the rat. Drugs Exp. Clin. Res.26:47–55 (2000). PubMedCAS Google Scholar
G. Kuhnle, J. P. Spencer, G. Chowrimootoo, H. Schroeter, E. S. Debnam, S. K. Srai, C. Rice-Evans, and U. Hahn. Resveratrol is absorbed in the small intestine as resveratrol glucuronide. Biochem. Biophys. Res. Commun.272:212–217 (2000) doi:10.1006/bbrc.2000.2750. ArticlePubMedCAS Google Scholar